Establishing the optimum adoptive immunotherapy model for
An effective mouse model for adoptive cancer immunotherapy targeting neoantigens
... positive metastatic breast cancer who was treated with both CD4 + and CD8 + T cells reactive to multiple neoantigens, including SLC3A2, KIAA0368, CADPS2, and CTSB (11). However, the response rate of mutation-reactive TIL ...
12
<p>Application Of Adoptive Immunotherapy In Ovarian Cancer</p>
... cell adoptive immunotherapy in OC is still being ...cell adoptive immu- notherapy for OC was recognized in 2007, and it was shown that resting NK cells rely on DNAM-1 signaling with complementary ...
17
Adoptive immunotherapy using tailored T-cell infusions
... mathematical model for immunotherapy in the context of published clinical ...chose immunotherapy by transfer of ex vivo expanded tumor-specific T cells for melanoma patients, as this therapeutic ...
9
Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology
... Beyond the limitation of most animal tumor models not faithfully recapitulating human cancer, for T cell therapy studies in partic- ular, model systems fall short because they fail to recapitulate the integrated ...
12
Cytokine-Induced Killer Cells as an Adoptive Cellular Immunotherapy Strategy for Hepatocellular Carcinoma
... Other culturing protocols for CIK cells to enhance proliferation or selective tumor toxicity with different cytokines combinations were reported. Helms et al. [39] used IL-12 to shorten the in vitro expansion process for ...
11
Co-transfer of tumor-specific effector and memory CD8+ T cells enhances the efficacy of adoptive melanoma immunotherapy in a mouse model
... to adoptive immunotherapy have used effector CD8+ T cells for their rapid prolif- erative capacity and ability to engage and clear tumor ...to adoptive immunotherapy using effector and memory ...
10
Adoptive immunotherapy of cancer with polyclonal, 108 fold hyperexpanded, CD4+ and CD8+ T cells
... stimulus such as anti-CD3 mAb that preserved the initial TCR repertoire diversity. Interestingly, anti-CD28 stimula- tion was not required for this experimental model, presumably because the T cells had already ...
12
BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models
... treatment model, the CD19 + NALM-6 leukemia cell line was transduced with pMX-EGFP-firefly lucif- erase for in vivo imaging studies, and 5 million of the cells were intrave- nously injected into NSG ...
17
Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation
... Female, five-week old NOD.Cg-Prkdc scid Il2rg tm1Wjl / SzJ (NSG) mice were purchased from the Jackson La- boratory (Bar Harbor, ME) and used at 6 weeks of age. For tumor xenotransplantation, 1 × 10 7 human PC-3 cancer ...
23
Research Article Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy
... Copyright © 2015 R. Ortenberg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
9
Importance of cyclophosphamide induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice
... to adoptive immunotherapy, rendering them highly susceptible to the antitumor activity of the immune spleen cells, provided that these cells were also stimulated by the simultaneous injec- tion of tumor ...
14
Adoptive immunotherapy: the time has come?
... Designer cells clear MRSA infection in a foreign-body infection mouse model. Designer cells applied in the cage achieved a 100% cure rate of acute MRSA infection[r] ...
31
Adoptive immunotherapy against ovarian cancer
... Cancer immunotherapy has recently emerged as a clinically effective tool in several solid tumors ...strategies, adoptive immunotherapy is considered one of the most promising ...options. ...
12
Adoptive T-cell transfer in cancer immunotherapy
... Practical considerations for adoptive cellular therapy Currently, cellular therapy remains a specialized area of thera- peutics that is relatively expensive and resource intensive. Cell processing facilities are ...
9
Challenges of Adoptive (T-)cell Transfer Immunotherapy for Cancer
... ACT-based immunotherapy as an accessible form of cancer treatment speaks to the inadequacies of the ACT approach that must not be ...based immunotherapy in order to garner widespread approval as an ...
41
Adoptive Cell Transfer: Is it a Promising Immunotherapy for Colorectal Cancer?
... effective immunotherapy strategy for patients with metastatic ...cancer immunotherapy strategies, ACT has several advantages: (1) tumor-specific lymphocytes can be selected, stimulated, and expanded to ...
17
Adoptive T cell therapy: Addressing challenges in cancer immunotherapy
... for adoptive T cell therapy to become a clinically significant modality that participates in the standard treatment of patients with malignant ...for adoptive therapy can take 4–16 weeks and for patients ...
8
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
... The treatment of patients with cancers expressing viral antigens. ACT can mediate cancer regression in humans with Epstein–Barr virus (EBv)-related lymphomas, which occur in patients receiving immunosuppressive drugs. ...
10
Memory T cell–driven differentiation of naive cells impairs adoptive immunotherapy
... For adoptive immunotherapies, where there is a strong inverse correlation between T cell differentiation and antitumor efficacy, the implications of our findings are clear: T Mem cause significantly enhanced ...
18
Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes
... 1 Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel. 2 Department of Urology, Sheba Medica Center, Tel Hashomer, Israel. 3 Department of Veterinary Resources, The Weizmann Institute of Science, ...
9